RetinAI is developing artificial intelligence technologies in order to “enable the right decisions sooner in healthcare,” co-founder and CEO, Dr Carlos Ciller, told OT at 100% Optical (28 February–2 March).
The company has developed a cloud-based medical image and data management platform, RetinAI Discovery, to enable clinicians to digest data at scale.
“Then, you can deploy an ever-growing collection of AI models,” he explained, “that enable you to identify and quantify different biomarkers.”
Practitioners in an optometry setting would be able to use the technology to potentially flag specific biomarkers, Ciller suggested.
“For instance, we have an optical coherence tomography biomarkers module, where we have a collection of different biomarkers specifically linked to the development of neurovascular age-related macular degeneration (AMD),” he shared.
Ciller demonstrated how the platform works to indicate a likelihood of the presence of specific biomarkers.
“We just give you the summary, so you have this equal view from the patient and the diseases in just a fraction of a second, so you can take faster, consistent, and efficient decisions with the same level of quality that an expert ophthalmologist would take,” he said.
Ciller also presented a scan for a patient with neurovascular AMD and the information available through the platform.
Asked about the security of data through the system, Ciller told OT: “We have implemented a very secure platform that enables you to securely share data with other parties.”
He continued: “If you are an optometrist working very closely with an ophthalmologist, you could refer a patient and give them access. There is continuity of the information that has been collected, so they don’t have to do the work again.”
Ciller shared: “We’re very proud to share that today, we have six approvals in the AI space.”
RetinAI’s algorithms are approved under EU-MDR for the analysis of data in OCT and in fundus imaging. The platform itself is certified as a medical device.
Reflecting on the technology, Ciller shared: “I see our company as connecting the dots. We are enabling the right decisions sooner in healthcare, and to do that, you need to make sure that whatever data has been captured in point A, has a seamless transfer into point B, enriching the information in the process.”
“Our AI technology is going to give you additional insights about the patient. It’s going to give you additional perspective, or summarising some perspectives, so you can take better decisions,” he said.
Sharing advice for optometrists who may be interested, but cautious, around the use of AI, Ciller recommended: “I think people should just give it a try, because they will be surprised how much technology is evolving.”
“I’m very proud of what the team has done over the past couple of years,” Ciller told OT, adding: “With our technologies, and other technologies out there, people really care about patient care and they are making these technologies available to the broader masses. So I think it’s worth giving it a try.”
Comments (0)
You must be logged in to join the discussion. Log in